(Q36469815)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

review article

1 reference

title

Current status of anti-angiogenesis therapy for prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Juan Antonio Jiménez

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Chinghai Kao

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Thomas A Gardner

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 May 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

260-268

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Tumor response to radiotherapy regulated by endothelial cell apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Tumor angiogenesis: therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Induction of angiogenesis during the transition from hyperplasia to neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Formation of endothelial cell networks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Vascular endothelial growth factor is a secreted angiogenic mitogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Involvement of Urokinase and its Receptor in the Invasiveness of Human Prostatic Carcinoma Cell Lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Expression of cyclooxygenase-2 in prostate carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Thrombospondins as anti-angiogenic therapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Thalidomide is an inhibitor of angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Angiostatin induces and sustains dormancy of human primary tumors in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Redefining the target: chemotherapeutics as antiangiogenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.11.022

10.1016/J.UROLONC.2005.11.022

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16678061%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference